Astellas is closing its stem cell therapy unit in Seattle, a site it acquired in 2018 with Universal Cells. The closure will impact around 55 employees and is part of a broader consolidation of research operations. The company aims to streamline its research footprint and enhance scientific collaboration.
What happened
Astellas is shutting down its Seattle site, formerly Universal Cells, as part of a move to consolidate its cell and gene therapy and oncology research efforts. The company will concentrate these activities at its existing sites in Westborough, Massachusetts, and South San Francisco, California. The Seattle site closure is expected to be completed by April 2028.
How many employees affected
Approximately 55 employees will be affected by the Seattle site closure. While a “handful” of employees may be offered relocation to other Astellas sites, the majority are expected to lose their jobs. The first wave of layoffs is scheduled to begin in July.
Why layoffs happened
The decision to close the Seattle site is part of Astellas' strategy to align its R&D organization for long-term sustainability. The company aims to improve efficiency, strengthen scientific collaboration, concentrate critical capabilities, and ensure its research platforms remain competitive and scalable.
Company background
Astellas is a global pharmaceutical company. It acquired Seattle-based Universal Cells in 2018 for $102.5 million, gaining access to Universal Donor Cell technology. This technology is designed to create cell therapy products that do not require human leukocyte antigen matching.
Industry impact
The closure reflects ongoing efforts within the pharmaceutical industry to consolidate research operations and optimize resource allocation. Astellas' move highlights the competitive pressures and the need for companies to streamline their research and development processes.
What's next
The Seattle site closure will occur gradually, with final closure expected by April 2028. Astellas has stated that it remains committed to advancing its research pipeline and the development of Universal Donor Cell technology. The company will focus its cell and gene therapy and oncology research in its Westborough and South San Francisco locations.
Source: fiercebiotech.com